29.89
price up icon0.07%   0.02
after-market After Hours: 29.99 0.10 +0.33%
loading
Genmab Adr stock is traded at $29.89, with a volume of 3.90M. It is up +0.07% in the last 24 hours and up +1.49% over the past month. Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
See More
Previous Close:
$29.87
Open:
$29.68
24h Volume:
3.90M
Relative Volume:
2.10
Market Cap:
$19.18B
Revenue:
$2.62B
Net Income/Loss:
$966.70M
P/E Ratio:
19.92
EPS:
1.5004
Net Cash Flow:
$1.09B
1W Performance:
-9.89%
1M Performance:
+1.49%
6M Performance:
+45.52%
1Y Performance:
+30.98%
1-Day Range:
Value
$29.46
$29.98
1-Week Range:
Value
$29.46
$31.50
52-Week Range:
Value
$17.23
$33.65

Genmab Adr Stock (GMAB) Company Profile

Name
Name
Genmab Adr
Name
Phone
-
Name
Address
-
Name
Employee
2,639
Name
Twitter
@Genmab
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
GMAB's Discussions on Twitter

Compare GMAB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GMAB
Genmab Adr
29.89 18.39B 2.62B 966.70M 1.09B 1.5004
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
421.39 108.36B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
463.43 60.82B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
577.95 61.02B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
817.32 50.01B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
310.81 34.05B 4.56B -176.77M 225.30M -1.7177

Genmab Adr Stock (GMAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-23-25 Upgrade Guggenheim Neutral → Buy
Apr-01-25 Downgrade Bernstein Mkt Perform → Underperform
Mar-11-25 Upgrade William Blair Mkt Perform → Outperform
Feb-13-25 Upgrade Leerink Partners Market Perform → Outperform
Oct-08-24 Initiated Redburn Atlantic Buy
Sep-04-24 Resumed Morgan Stanley Equal-Weight
Aug-20-24 Downgrade JP Morgan Overweight → Neutral
Jul-15-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-23-24 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-22-24 Downgrade Citigroup Neutral → Sell
Dec-06-23 Upgrade UBS Neutral → Buy
Nov-10-23 Upgrade Deutsche Bank Hold → Buy
Nov-08-23 Upgrade DNB Markets Sell → Buy
Oct-18-23 Initiated Exane BNP Paribas Underperform
Sep-06-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-24-23 Initiated BTIG Research Buy
Jul-14-23 Initiated HSBC Securities Buy
May-31-23 Initiated UBS Neutral
May-12-23 Initiated Morgan Stanley Underweight
Dec-20-22 Downgrade Citigroup Buy → Neutral
Nov-14-22 Initiated William Blair Mkt Perform
Nov-11-22 Downgrade Deutsche Bank Buy → Hold
Jun-24-22 Initiated BMO Capital Markets Market Perform
May-02-22 Initiated Cowen Market Perform
Mar-16-22 Upgrade UBS Neutral → Buy
Jan-31-22 Upgrade H.C. Wainwright Neutral → Buy
Jan-03-22 Downgrade Guggenheim Buy → Neutral
Dec-01-21 Initiated Berenberg Sell
Sep-16-21 Downgrade Jefferies Buy → Hold
Sep-07-21 Downgrade Morgan Stanley Equal-Weight → Underweight
Aug-24-21 Downgrade H.C. Wainwright Buy → Neutral
Apr-20-21 Initiated Deutsche Bank Buy
Jan-19-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-20 Downgrade Bryan Garnier Neutral → Sell
Sep-08-20 Initiated SVB Leerink Mkt Perform
Jun-25-20 Downgrade Credit Suisse Outperform → Neutral
Apr-23-20 Initiated Credit Suisse Outperform
Feb-24-20 Reiterated H.C. Wainwright Buy
Jan-13-20 Initiated SunTrust Buy
Dec-12-19 Downgrade Deutsche Bank Buy → Hold
Sep-13-19 Upgrade BofA/Merrill Neutral → Buy
Sep-12-19 Upgrade JP Morgan Neutral → Overweight
Aug-12-19 Initiated Guggenheim Buy
Aug-12-19 Initiated Morgan Stanley Overweight
Aug-12-19 Initiated RBC Capital Mkts Outperform
View All

Genmab Adr Stock (GMAB) Latest News

pulisher
Oct 20, 2025

Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 20, 2025
pulisher
Oct 20, 2025

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Oct 20, 2025
pulisher
Oct 18, 2025

HC Wainwright Has Pessimistic View of Genmab A/S Q2 Earnings - Defense World

Oct 18, 2025
pulisher
Oct 18, 2025

Genmab A/S’s (GMAB) “Buy” Rating Reiterated at HC Wainwright - Defense World

Oct 18, 2025
pulisher
Oct 16, 2025

Truist Financial Corp Reduces Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World

Oct 16, 2025
pulisher
Oct 16, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Oct 16, 2025
pulisher
Oct 16, 2025

Genmab A/S FY2026 EPS Estimate Reduced by Leerink Partnrs - Defense World

Oct 16, 2025
pulisher
Oct 14, 2025

GMAB or TECH: Which Is the Better Value Stock Right Now? - sharewise.com

Oct 14, 2025
pulisher
Oct 14, 2025

CD40 Targeting Therapy Clinical Trials Anti CD40 Antibody Therapy Market Opportunity Assessment Insight - GlobeNewswire Inc.

Oct 14, 2025
pulisher
Oct 14, 2025

Q3 EPS Estimates for Genmab A/S Lowered by Leerink Partnrs - MarketBeat

Oct 14, 2025
pulisher
Oct 14, 2025

31,681 Shares in Genmab A/S Sponsored ADR $GMAB Purchased by Callan Family Office LLC - MarketBeat

Oct 14, 2025
pulisher
Oct 13, 2025

Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 13, 2025
pulisher
Oct 13, 2025

Genmab A/S Sponsored ADR $GMAB Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat

Oct 13, 2025
pulisher
Oct 13, 2025

William Blair Brokers Lift Earnings Estimates for Genmab A/S - MarketBeat

Oct 13, 2025
pulisher
Oct 12, 2025

DAVENPORT & Co LLC Grows Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World

Oct 12, 2025
pulisher
Oct 11, 2025

Wealth Enhancement Advisory Services LLC Buys New Shares in Genmab A/S Sponsored ADR $GMAB - Defense World

Oct 11, 2025
pulisher
Oct 09, 2025

QRG Capital Management Inc. Sells 8,945 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat

Oct 09, 2025
pulisher
Oct 07, 2025

AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 07, 2025
pulisher
Oct 06, 2025

Genmab A/S (NASDAQ:GMAB) Sets New 1-Year HighHere's Why - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal - sharewise.com

Oct 06, 2025
pulisher
Oct 04, 2025

Genmab AS (GMAB) Stock Price, Trades & News - GuruFocus

Oct 04, 2025
pulisher
Oct 03, 2025

What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now? - sharewise.com

Oct 03, 2025
pulisher
Oct 03, 2025

Why Genmab Stock Popped on Friday - The Globe and Mail

Oct 03, 2025
pulisher
Oct 03, 2025

Leerink Partnrs Weighs in on Genmab A/S FY2027 Earnings - Defense World

Oct 03, 2025
pulisher
Oct 03, 2025

Best Momentum Stock to Buy for October 3rd - sharewise.com

Oct 03, 2025
pulisher
Oct 03, 2025

Genmab A/S (NASDAQ:GMAB) Price Target Raised to $40.00 at HC Wainwright - Defense World

Oct 03, 2025
pulisher
Oct 03, 2025

Genmab A/S Sponsored ADR $GMAB Stock Position Lowered by Signaturefd LLC - Defense World

Oct 03, 2025
pulisher
Oct 03, 2025

New Strong Buy Stocks for October 3rd - Yahoo Finance

Oct 03, 2025
pulisher
Oct 02, 2025

Leerink Partnrs Comments on Genmab A/S FY2027 Earnings - MarketBeat

Oct 02, 2025
pulisher
Oct 01, 2025

Genmab A/S Updates Articles of Association to Enhance Growth Strategy - The Globe and Mail

Oct 01, 2025
pulisher
Oct 01, 2025

FY2025 EPS Estimates for Genmab A/S Boosted by William Blair - MarketBeat

Oct 01, 2025
pulisher
Oct 01, 2025

Park Avenue Securities LLC Acquires 832 Shares of Genmab A/S Sponsored ADR $GMAB - Defense World

Oct 01, 2025
pulisher
Sep 30, 2025

TD Cowen Remains a Hold on Genmab (GMAB) - The Globe and Mail

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab A/S (NASDAQ:GMAB) Sets New 52-Week HighWhat's Next? - MarketBeat

Sep 30, 2025
pulisher
Sep 30, 2025

TD Private Client Wealth LLC Has $130,000 Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume on Analyst Upgrade - Defense World

Sep 30, 2025
pulisher
Sep 29, 2025

Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase After Analyst Upgrade - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

Trending tickers: Alibaba, AstraZeneca, GSK, Stellantis and Genmab - Yahoo

Sep 29, 2025
pulisher
Sep 29, 2025

European Stocks Higher to Kick Off the Week - TradingView

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab A/S Sponsored ADR $GMAB Shares Sold by Fifth Third Bancorp - Defense World

Sep 29, 2025
pulisher
Sep 29, 2025

Before the bell: futures up, Lufthansa cuts jobs, GSK CEO steps down - TradingView

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - Placera.se

Sep 29, 2025
pulisher
Sep 25, 2025

Genmab A/S (NASDAQ:GMAB) Upgraded by Guggenheim to Buy Rating - Defense World

Sep 25, 2025
pulisher
Sep 25, 2025

Genmab A/S Sponsored ADR $GMAB Shares Purchased by Parallel Advisors LLC - Defense World

Sep 25, 2025
pulisher
Sep 25, 2025

Rhumbline Advisers Increases Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World

Sep 25, 2025

Genmab Adr Stock (GMAB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$91.28
price up icon 2.21%
$37.26
price up icon 1.11%
$105.66
price up icon 0.87%
$159.66
price down icon 0.29%
biotechnology ONC
$310.81
price up icon 0.25%
Cap:     |  Volume (24h):